CJC-1295 — Wolverine Health

How it works

A synthetic GHRH analog that stimulates GH release via the GHRH receptor. The DAC-modified version binds plasma albumin, extending the half-life from minutes to days. A Phase II human trial in healthy adults showed sustained GH and IGF-1 elevation over weeks. What it does in terms of body composition or performance in non-deficient adults — that part hasn't been tested rigorously.

FDA status: No FDA approval. Not on the PCAC July 2026 review docket.
WADA status: Permitted in sport
Route: subcutaneous injection

Key studies

CJC-1295 stimulates GH and IGF-1 secretion in healthy adults — Teichman et al. (2006)

CJC-1295 with DAC produced sustained elevation of GH and IGF-1 in healthy adults across multiple dose levels in a Phase II trial, with a half-life of 6–8 days.

Wolverine Health is building physician-supervised peptide protocols. Get early access.

Join the waitlist

Research on CJC-1295

The peptide the FDA already voted against

Everyone heard "peptides are coming back." Almost nobody heard that the FDA already sat down with some of the most-stacked ones and voted no. Here's which, when, and what a July 2026 yes would actually buy you.

Peptide access by US state: why the regulatory patchwork right now is real

The federal compounding framework applies the same way in every state. The state pharmacy boards do not. The result is a real state-by-state patchwork that decides whether a telehealth prescription for a compounded peptide is actually fillable where you live.

What RFK Jr.'s February 2026 announcement actually said about peptides

The "announcement" was a Joe Rogan appearance, not a Federal Register notice. The wellness scene heard one thing. The actual signal was narrower, and the rulemaking that turns it into access is still more than a year away.

Growth hormone secretagogues: the peptides that turn your own growth hormone back up

WADA

CJC-1295, ipamorelin, sermorelin, and tesamorelin share one job — getting your own pituitary to release more growth hormone, the repair-and-recovery signal that fades after your twenties. Here is the appeal, the two peptide families inside the class, and how far the human proof actually goes.

CJC-1295 vs ipamorelin: which growth-hormone peptide is the right tool for you?

WADA

CJC-1295 and ipamorelin are the internet's favourite growth-hormone pairing — but they do two different jobs. One raises your GH baseline for days from a single shot; the other fires a clean nightly pulse. Here's what each could do for you, which fits which goal, and why so many people run both.

CJC-1295: turning your own growth hormone back up

WADA

CJC-1295 is engineered to make your own pituitary release growth hormone for days from a single shot — and unusually, a real human trial says it works. Here's what that could mean for recovery, sleep and body composition, how far the proof goes, and why one name hides two different compounds.

CJC-1295: One 2006 Study, Eighteen Years of Weekly Use

WADA

CJC-1295 reliably raises GH and IGF-1 in humans, confirmed by a single 2006 pharmacokinetic study. Whether that translates into any functional benefit has never been tested.